Roche and Genentech to use SurModics tech for Lucentis delivery
This article was originally published in Clinica
Executive Summary
Roche and its subsidiary Genentech have bought an excusive licence for SurModics’ drug delivery system, which uses biodegradable microparticles. The firms will use the technology to develop and commercialise a sustained drug delivery formulation of Lucentis, a monoclonal antibody fragment used to treat age-related macular degeneration (AMD). Under the terms of the agreement, SurModics will receive an up-front payment of $3.5m. However, the Eden Prairie, Minnesota-based firm could receive up to $200m in fees and milestone payments, contingent on the successful development and commercialisation of multiple products.